Faculty profile

Tracy McGaha

ResearcherUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.

Tracy McGaha

Researcher

Health Sciences

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
4 publications in the last five years, latest in 2026.
Senior (last) author on 1 recent paper, a sign of leading a research group.
Principal investigator on 5 research grants (5 CIHR), most recently in 2025.
Supervised 2 trainees who won CIHR awards, most recently in 2021.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Tumor Immunology Pancreatic Cancer Macrophage And Dendritic Cells B Cells T Cells Macrophages Neutrophils Chemotherapy

Latest papers

CRISPR screen reveals regulators of age-associated CD8+ T cell dysfunction in cancer.
Nature reviews. Immunology · 2026 · senior author
A retrospective analysis exploring the association of pretreatment neutrophil-to-lymphocyte ratio and immune checkpoint inhibitor outcomes in patients with advanced NSCLC and liver metastases.
Therapeutic advances in medical oncology · 2025
Ex vivo activation of the GCN2 pathway metabolically reprograms T cells, leading to enhanced adoptive cell therapy.
Cell reports. Medicine · 2024

All 6 publications

Latest funding

Characterizing meningioma heterogeneity and microenvironment for new therapeutic opportunities
CIHR · 2025 · Co-investigator
$787,952
Using spatially defined analysis of TCR and BCR repertoires for analysis of immune evolution and lymphocyte clonal selection in pancreatic cancer
CIHR · 2025 · Nominated PI
$1,357,875
The role of ADO in cancer biology
CIHR · 2025 · Co-investigator
$1,124,550

All 16 grants and awards

6 publications.

CRISPR screen reveals regulators of age-associated CD8+ T cell dysfunction in cancer.

Bianca M, McGaha T

Nature reviews. Immunology2026Senior author

DOI: 10.1038/s41577-026-01308-z PMID: 42086868

A retrospective analysis exploring the association of pretreatment neutrophil-to-lymphocyte ratio and immune checkpoint inhibitor outcomes in patients with advanced NSCLC and liver metastases.

Makarem M, Hoang T, Elliott MJ, Rabinovitch A, Hueniken K, Kuang S, Schmid S, Tsao MS, McGaha T, Ohashi PS, Shepherd FA, Bradbury PA, Liu G, Leighl NB, Sacher A, Lau SCM

Therapeutic advances in medical oncology2025

DOI: 10.1177/17588359251367315 PMID: 41164205

Ex vivo activation of the GCN2 pathway metabolically reprograms T cells, leading to enhanced adoptive cell therapy.

St Paul M, Saibil SD, Kates M, Han S, Lien SC, Laister RC, Hezaveh K, Kloetgen A, Penny S, Guo T, Garcia-Batres C, Smith LK, Chung DC, Elford AR, Sayad A, Pinto D, Mak TW, Hirano N, McGaha T, Ohashi PS

Cell reports. Medicine2024

DOI: 10.1016/j.xcrm.2024.101465 PMID: 38460518

N6-Methyladenosine Reader YTHDF1 Promotes ARHGEF2 Translation and RhoA Signaling in Colorectal Cancer.

Wang S, Gao S, Zeng Y, Zhu L, Mo Y, Wong CC, Bao Y, Su P, Zhai J, Wang L, Soares F, Xu X, Chen H, Hezaveh K, Ci X, He A, McGaha T, O'Brien C, Rottapel R, Kang W, Wu J, Zheng G, Cai Z, Yu J, He HH

Gastroenterology2022

DOI: 10.1053/j.gastro.2021.12.269 PMID: 34968454

An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE).

Clouthier DL, Lien SC, Yang SYC, Nguyen LT, Manem VSK, Gray D, Ryczko M, Razak ARA, Lewin J, Lheureux S, Colombo I, Bedard PL, Cescon D, Spreafico A, Butler MO, Hansen AR, Jang RW, Ghai S, Weinreb I, Sotov V, Gadalla R, Noamani B, Guo M, Elston S, Giesler A, Hakgor S, Jiang H, McGaha T, Brooks DG, Haibe-Kains B, Pugh TJ, Ohashi PS, Siu LL

Journal for immunotherapy of cancer2019

DOI: 10.1186/s40425-019-0541-0 PMID: 30867072

Chemo-Immunotherapy: Role of Indoleamine 2,3-Dioxygenase in Defining Immunogenic Versus Tolerogenic Cell Death in the Tumor Microenvironment.

Johnson TS, Mcgaha T, Munn DH

Advances in experimental medicine and biology2017

DOI: 10.1007/978-3-319-67577-0_7 PMID: 29275467

Something wrong or missing on this profile? Suggest a correction

Tracy McGaha

Research

Latest papers

Latest funding

CRISPR screen reveals regulators of age-associated CD8+ T cell dysfunction in cancer.

A retrospective analysis exploring the association of pretreatment neutrophil-to-lymphocyte ratio and immune checkpoint inhibitor outcomes in patients with advanced NSCLC and liver metastases.

Ex vivo activation of the GCN2 pathway metabolically reprograms T cells, leading to enhanced adoptive cell therapy.

N6-Methyladenosine Reader YTHDF1 Promotes ARHGEF2 Translation and RhoA Signaling in Colorectal Cancer.

An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE).

Chemo-Immunotherapy: Role of Indoleamine 2,3-Dioxygenase in Defining Immunogenic Versus Tolerogenic Cell Death in the Tumor Microenvironment.

Characterizing meningioma heterogeneity and microenvironment for new therapeutic opportunities

Using spatially defined analysis of TCR and BCR repertoires for analysis of immune evolution and lymphocyte clonal selection in pancreatic cancer

The role of ADO in cancer biology

Mutations in pancreatic cancer cause increased sterol efflux and immune dysfunction in pancreatic cancer.

Mechanistic investigations of the innate immune response to cancer cell death and immune tolerance to solid tumor antigens.

Characterization of the T cell populations that regulate autoimmunity in asymptomatic anti-nuclear positive individuals and how they become altered in early untreated systemic autoimmune rheumatic disease

Targeting protein arginine methylation in the 9p21.3 loss tumor microenvironment

Targeting protein arginine methylation in tumor-associated macrophages

Investigating the effects of the microbiome and the aryl hydrocarbon receptor on CD8+ T cell function in pancreatic ductal adenocarcinoma

Identification of the immunologic mechanisms leading to flares of disease activity in Systemic Lupus Erythematosus

Frequent collaborators

Anna Spreafico

David Cescon

Adrian Sacher

Stephanie Lheureux

Geoffrey Liu

Robert Rottapel

Catherine O'Brien

Gang Zheng

Benjamin Haibe-Kains

Naoto Hirano

Tracy McGaha

Research

Latest papers

Latest funding

CRISPR screen reveals regulators of age-associated CD8+ T cell dysfunction in cancer.

A retrospective analysis exploring the association of pretreatment neutrophil-to-lymphocyte ratio and immune checkpoint inhibitor outcomes in patients with advanced NSCLC and liver metastases.

Ex&#xa0;vivo activation of the GCN2 pathway metabolically reprograms T&#xa0;cells, leading to enhanced adoptive cell therapy.

N6-Methyladenosine Reader YTHDF1 Promotes ARHGEF2 Translation and RhoA Signaling in Colorectal Cancer.

An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE).

Chemo-Immunotherapy: Role of Indoleamine 2,3-Dioxygenase in Defining Immunogenic Versus Tolerogenic Cell Death in the Tumor Microenvironment.

Frequent collaborators

Anna Spreafico

David Cescon

Adrian Sacher

Stephanie Lheureux

Geoffrey Liu

Robert Rottapel

Catherine O'Brien

Gang Zheng

Benjamin Haibe-Kains

Naoto Hirano

Ex vivo activation of the GCN2 pathway metabolically reprograms T cells, leading to enhanced adoptive cell therapy.